Company intelligence / Profile preview

Pharmorphix

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Pharmorphix is a leading provider of solid form, pre-formulation, and particle engineering services to the pharmaceutical and biotechnology industries. Since its founding in 2003, it has completed over 2,000 customer projects involving structurally diverse APIs. Its technology has contributed to nearly 20% of FDA-approved small molecule drugs over the past decade. The company does not develop its own therapeutics but enables client drug candidates through advanced solid-state chemistry expertise.

Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

Works with major global pharmaceutical and biotech companies as clients but no specific partnerships disclosed publicly.

Beyond the preview

Go deeper on Pharmorphix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmorphix.

Explore the full profile